Core Viewpoint - The article discusses the advancements and challenges in the cell and gene therapy (CGT) industry, highlighting the innovative approach of Huakan Bio in developing 3D cell culture technology to reduce costs and improve scalability in cell therapy production [3][4][6]. Industry Overview - CGT is seen as a promising direction for curing major diseases like cancer and rare diseases, but the high cost of treatments, often exceeding $1.5 million (approximately 10.8 million RMB) per course, poses a significant barrier for patients [3]. - The industry faces a fundamental challenge in scaling up the production of precious cells from laboratory settings to meet patient needs efficiently and cost-effectively [3]. Company Profile - Huakan Bio, founded in August 2018 by Tsinghua University professor Du Yanan and his two doctoral students, focuses on 3D microcarrier technology to enhance cell growth and automate production processes, significantly improving efficiency and reducing costs [4][6]. - The company has successfully launched China's first stem cell drug, "Aimi Maitosai Injection," priced at 19,800 RMB per course, which is about 1/70th the price of similar products in the U.S. [6]. Technology and Innovation - Huakan Bio's core technology, the 3D microcarrier, provides a three-dimensional growth environment for cells, enhancing their natural function and scalability compared to traditional 2D culture methods [13]. - The 3D microcarrier technology allows for a cell yield increase of one to two orders of magnitude, with a recovery rate exceeding 98%, supporting the cultivation of billions of cells in a single batch [13][14]. Market Position and Growth - The company has completed multiple funding rounds, with significant investments from various institutions, and has established itself as a leading player in the domestic 3D cell manufacturing sector [15][17]. - Huakan Bio's international business has expanded rapidly, covering over 20 countries, with a growth rate exceeding 200% in 2025 [21]. Future Outlook - The global CGT market is expected to grow rapidly, with China identified as a core market. Huakan Bio aims to leverage its unique technology to meet the increasing demand for scalable and automated cell culture solutions [21].